Blue Horseshoe Stocks: Options, Updates & More

Twitter, Inc. TWTR – Options Recap

Our formulated ideas for the TWTR options chain from yesterday morning’s premarket report turned out to offer up some fantastic chances to profit. We spotted just the right conditions before market hours and pounced, designating the TWTR Weekly $15-16 Calls to be our targets.

It certainly wasn’t the first time we’ve used Twitter in this manner, and it probably won’t be the last. Regardless of which set of contracts was chosen, multi-bag, single-session gains were there for the taking:

$15 Calls – Range: .30-1.49 – Max Gain: 397%
$15.50 Calls – Range: .40-1.00 – Max Gain: 150%
$16 Calls – Range: .21-.61 – Max Gain: 190%
_________

FRESH Options Idea: UPS 05/05 $108-111 Calls


Akebia Therapeutics, Inc. AKBA

An honorable mention from yesterday’s report was AKBA, which we tagged for observation after noticing some abnormal premarket activity on our routine morning scan.

The stock traded in a respectable range from a low of 11.08 to as high as 13.94. That works out to an intraday move of 26% which came on massive volume of an astonishing 110X the 30-day average! It also managed to close holding roughly half of its daily increase at 12.50, so we’re definitely going to be on the lookout for continued activity in AKBA, which could include a dip-and-rip pattern at some point.


American Leisure Holdings, Inc. AMLH

We tracked AMLH over some monstrous gains from the end of March, to earlier this month. The move took it from super-subpenny lows of .0003 to a high of .007 (+2233%), so we weren’t at all surprised to see a consolidation period follow over the next several sessions.

The stock did however find support and make a reversal off of the .0029 level beginning last week, and heading back up to its previous high of .007 yesterday, marking a 141% swing. We’ll look for the stock to break through that resistance at .007, which would effectively put AMLH into Blue Sky Breakout mode, and trading at its highest prices since the Fall of 2015.


Extended Watchlist:
ALIM, BLDV, MDGS, SSKN, SINO, PURA(News)

Blue Horseshoe Stocks: Options, Bottom-Plays & More

Twitter, Inc. TWTR – Options Idea

We have yet to talk about TWTR in 2017, namely because the stock has been in an overall downtrend over nearly that whole span. However, in recent weeks, it found a bottom and slowly has begun stair-stepping its way to a recovery. That process is getting a kick in the pants this morning with a significant morning gap up on the heels of Twitter’s earnings. The company posted losses, though not as big as expected, while also reporting an increase in users.

We’re going to see about possibly using the commotion to our advantage with a range of options ideas. Provided TWTR can maintain support at or above its 50DMA (15.19) on any pullbacks, we’re going to be interested in tracking the activity in the TWTR Weekly $15-16 Calls, on which we’ll be looking for a classic dip-and-rip pattern. If properly timed, it could spell some big gains in those contracts.


Apricus Biosciences, Inc. APRI

We want to put APRI on our radars today as a potential bottom-bouncer. At the beginning of the year, from a level comparable to current prices, the stock ran into the mid-$3 range. Now, after a long period of getting beat back nearly to its annual low, it is showing signs of a rebound that we’d like to monitor on the chance that it turns into a full-scale reversal.

You can see just what we mean on the snapshot below. The RSI is indicating that APRI is about to enter extreme oversold territory, while the MACD is just beginning to curl upward and show some convergence. We wouldn’t be surprised to a see cross in the days ahead.

Even just a run back to the 200DMA from here would be a move of almost 100% so we’ll definitely want to keep an eye peeled.

.


NoHo, Inc. DRNK

We’ve been saying how hot the super-subpenny market has been recently, and the trend has been persisting now for quite some time.  We initially slated DRNK for observation in Monday’s premarket report, after which we saw a soild 70% pop from a low of .0003. We stated as much in yesterday’s report, mentioning that we’d certainly want to continue to pay attention, based on a number of factors.

The stock did manage to record a new high for us for the second straight day, making an intraday move of 50% from .0004-.0006, and extending our two-session observed range to a nice, round 100%


Extended Watchlist:
AAGC, KALY, AKBA, CETV, SDLP, UQM

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)


Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.


Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.


Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: Bottom-Plays, Options & More

Novavax, Inc. NVAX

Our first item of interest this morning is going to be NVAX. This play set off our alarms on Friday when the stock was downgraded on the heels of ill-received trial data on the company’s RSV (respiratory syncytial virus) vaccine.

Whenever we see knee-jerk reactions take place, and Friday’s backslide of more than 80% certainly qualifies in that category, we like to place the battered stocks on watch for the subsequent recoveries that occur as often as not.

With the monster gap that Friday’s activity left on the chart (1.20′s to 8.10′s), it will be very interesting to see how the stock responds as we kick off a fresh trading week. Prior to that it had been on a fairly steady four month uptrend that almost reached the 100%-mark. All these factors playing in at once are plenty enough to reserve a slot for NVAX on our radars in coming sessions.


Netflix, Inc. NFLX – Options Idea

We’ve tracked NFLX options to great success on multiple occasion in the past, and today seems like a good time to take another run at it. Along with being on the uptrend for the past six or seven weeks, the stock breached its 200DMA in a bullish manner on Friday, a signal that further advances could be in the cards this week. NFLX is gapping up slightly in the premarket this morning.

In accordance, we want to have an options idea ready and waiting to take advantage should a continued surge be in the cards. The targets we want to zero in on are the NFLX Weekly $99.50-101 Calls for potential swing trades.



APT Systems, Inc. APTY

We alerted our readers to a PR put out by APTY on Friday alluding to the planned purchase of shares out of the open market by the company’s CEO. That coincided with a reasonable amount of momentum that the stock had carried into that session from the one prior.

We mentioned that we liked the chances of the stock seeing some further increases for Friday’s session, and we weren’t disappointed on that front. APTY traded in a solid range from .0032 to .0044, a respectable intraday gain totaling 38%

We’ll remain interested in this play provided it can maintain support above Friday’s swing-low of .0032.


Extended Watchlist:
USLV, CFRX, NWBO, AKBA, ETRM, PTIE

Blue Horseshoe Stocks: SPY Options Recap & More

SPY Options Update

We were so spot-on with our options alert on the SPY in yesterday’s premarket report, that we feel it necessary to quote our alert verbatim. We stated: “With another reversal appearing likely with this morning’s gap-up in the markets, we’ll want to swing our attention in the opposite direction. The SPY generally trades inversely to the UXVY, thus we’ll be monitoring SPY Weekly $195-197 Calls in the event of a continued uptrend signal.” 

We certainly hope a good number of our readers were able to catch that, as every single one of the contract sets in our targeted range could have facilitated sizable gains on the session. Here’s a breakdown of the possibilities:

$195 Calls  – Daily Range: 2.05-3.50 – Max Gain: 71%
$195.50 Calls  – Daily Range: 1.75-3.15 – Max Gain: 80%
$196 Calls  – Daily Range: 1.48-2.80 – Max Gain: 89%
$196.50 Calls  – Daily Range: 1.25-2.45 – Max Gain: 96%
$197 Calls  – Daily Range: 1.01-2.15 – Max Gain: 113%

In order to take advantage of the SPY moving forward, we’ll need to see a continued boost in stocks. In that event, we may look to roll our strike prices closer to the money, namely the Weekly $198-200.50 Calls.


Apple to Announce iPhone 6S Plus – Options Idea

With Apple officially announcing the release of the iPhone 7 today, which is slated to go on sale at the end of next week, we’re going to want to stay ready for the possibility of an options play to one side or the other. We’ll need to guage public reaction to the new phone; an underwhelming product could result in a PPS decline for AAPL, in which case we’d be monitoring Weekly $112-50-114.50 Puts. In the event of a mainly positive reaction, of course, we’d flip that idea to the Call-side in the same strike price range.


Akebia Therapeutics, Inc. AKBA

AKBA is undergoing a mega gap-up in premarket trading today, largely due to yesterday’s after-hours report of positive Phase II study results. We’ll look to possibly take advantage of the situation; with such a rapid move up, it leaves AKBA open to a dip-and-rip pattern on the chart when sellers come out of the woodwork to take profits off of the table.

We’ve pointed out the previous swing highs as levels at which AKBA will need to maintain support on the dip, in order for us to remain interested:

Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease (Tue, Sep 8)


Extended Watchlist:
UAPC, CCTC, TPIV, ASTI